Study Finds Excellent Outcomes for Intermediate Risk Prostate Cancer Patients Treated with Isoray’s Cesium-131
March 02 2022 - 8:13AM
Investigators from the University of Pittsburgh School of
Medicine have published a clinical study that demonstrates
excellent outcomes for localized intermediate-risk prostate cancer
patients treated with Isoray’s Cesium-131 brachytherapy,
commercially known as Cesium Blu.
The published article on the study, Treatment of
intermediate-risk prostate cancer with Cs-131: Long-term results
from a single institution, was authored by Joshua L.
Rodríguez-López, MD, Ankur K. Patel, MD, Ronald M. Benoit, MD,
Sushil Beriwal, MD, Ryan P. Smith, MD, University of Pittsburgh
School of Medicine, Pittsburgh, Pennsylvania. The peer reviewed
paper was published in the January-February 2022 issue of
BRACHYTHERAPY, an international multidisciplinary journal of the
American Brachytherapy Society. The study analyzed the outcomes for
335 intermediate-risk prostate cancer patients treated with
Cesium-131 brachytherapy.
Study patients had significant follow-up time. The median
follow-up was 5.8 years, with a range of 4 to 8.9 years. The study
found both the “favorable” (147 patients) and “unfavorable” (188
patients) intermediate-risk groups demonstrated excellent
biochemical outcomes. Those outcomes were 97.6% and 91.4%
respectively at five years. For 135 “favorable” patients treated
with Cesium-131 implant alone (excluding 12 patients who were
treated with external beam radiation therapy and Cesium-131
implant), the outcome was 98.1%.
Intermediate-risk prostate cancer can be classified as
“favorable” (FIR) or “unfavorable” (UIR). In localized prostate
cancer, risk increases as PSA (prostate-specific antigen), tumor
grade, and tumor stage advance, creating higher risk of treatment
failure.
Study author Dr. Ryan P. Smith, MD, said, “The biggest thing we
wanted to accomplish in analyzing this data was to try to
individualize treatment because the intermediate risk group is the
most heterogenous. We used Cesium-131 to decrease the duration of
acute toxicity as compared to other radio isotopes because of its
shorter half-life. For favorable patients, it is very clear that
all you need is Cesium-131 prostate brachytherapy. For unfavorable
patients, the combination of external beam radiation followed by
Cesium-131 prostate brachytherapy allows us to avoid hormonal
therapy for most patients.”
The study adds convincing data to the more than 14 years of
accumulated experience with Cesium-131 prostate brachytherapy
treatment and builds on the body of literature to support the use
of this isotope.
Commenting on the study, Isoray CEO Lori Woods said, “We are
very excited by the results of this study. We believe the import of
these findings is significant. We further believe this study
provides compelling evidence that strongly suggests patients
diagnosed with intermediate-risk prostate cancer should be
presented with Cesium-131 as a valuable treatment opportunity by
clinicians.”
Isoray is a medical technology company and innovator in seed
brachytherapy. The Company is the world’s only producer of
Cesium-131 brachytherapy, which is powering expanding internal
radiation treatment options throughout the body for prostate cancer
as well as difficult to treat head and neck, brain, lung,
gynecologic, pelvic, and colorectal cancers.
About
IsorayIsoray, Inc.,
through its subsidiary, Isoray Medical, Inc. is the sole producer
of Cesium-131 brachytherapy seeds, commercially known as Cesium
Blu, which are expanding brachytherapy options throughout the body.
Learn more about this innovative Richland, Washington company and
explore the many benefits and uses of Cesium-131 by visiting
www.isoray.com. Follow us on LinkedIn and Twitter. Join us on
Facebook.
Safe Harbor StatementStatements in this news
release about Isoray's future expectations, including: efficacy of
the biochemical success rate for 4 and 9 year results with or
without external beam radiation, the advantages of our products and
their delivery systems, whether additional studies are released
that support the conclusions of the study discussed in this news
release, whether interest in and use of our products will increase
or continue, and all other statements in this release, other than
historical facts, are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995
("PSLRA"). This statement is included for the express purpose of
availing Isoray, Inc. of the protections of the safe harbor
provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of our products, our ability
to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to
meet demand within required delivery time periods while meeting our
quality control standards, our ability to enforce our intellectual
property rights, whether additional studies are released that
support the conclusions of past studies, whether ongoing patient
results with our products are favorable and in line with the
conclusions of clinical studies and initial patient results,
patient results achieved when our products are used for the
treatment of cancers and malignant diseases, successful completion
of future research and development activities, whether we, our
distributors and our customers will successfully obtain and
maintain all required regulatory approvals and licenses to market,
sell and use our products in its various forms, continued
compliance with ISO standards, the success of our sales and
marketing efforts, changes in reimbursement rates, the procedures
and regulatory requirements mandated by the FDA for 510(k) approval
and reimbursement codes, changes in laws and regulations applicable
to our products, the scheduling of physicians who either delay or
do not schedule patients in periods anticipated, the use of
competitors' products in lieu of our products, less favorable
reimbursement rates than anticipated for each of our products, and
other risks detailed from time to time in Isoray's reports filed
with the SEC. Unless required to do so by law, we undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact
Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910
IsoRay (AMEX:ISR)
Historical Stock Chart
From Mar 2024 to Apr 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2023 to Apr 2024